AIM ImmunoTech Statistics
Total Valuation
AIM ImmunoTech has a market cap or net worth of $5.83 million. The enterprise value is $4.52 million.
| Market Cap | 5.83M |
| Enterprise Value | 4.52M |
Important Dates
The next estimated earnings date is Friday, August 14, 2026, after market close.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AIM ImmunoTech has 22.08 million shares outstanding. The number of shares has increased by 313.35% in one year.
| Current Share Class | 22.08M |
| Shares Outstanding | 22.08M |
| Shares Change (YoY) | +313.35% |
| Shares Change (QoQ) | +50.85% |
| Owned by Insiders (%) | 0.72% |
| Owned by Institutions (%) | 0.80% |
| Float | 19.33M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 62.02 |
| Forward PS | n/a |
| PB Ratio | 1.02 |
| P/TBV Ratio | 12.59 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 48.14 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.01, with a Debt / Equity ratio of 2.15.
| Current Ratio | 1.01 |
| Quick Ratio | 0.96 |
| Debt / Equity | 2.15 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -10.35 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -86.56% |
| Return on Invested Capital (ROIC) | -239.35% |
| Return on Capital Employed (ROCE) | -420.94% |
| Weighted Average Cost of Capital (WACC) | 13.59% |
| Revenue Per Employee | $4,476 |
| Profits Per Employee | -$632,190 |
| Employee Count | 21 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -90.37% in the last 52 weeks. The beta is 1.19, so AIM ImmunoTech's price volatility has been higher than the market average.
| Beta (5Y) | 1.19 |
| 52-Week Price Change | -90.37% |
| 50-Day Moving Average | 0.36 |
| 200-Day Moving Average | 0.92 |
| Relative Strength Index (RSI) | 44.46 |
| Average Volume (20 Days) | 709,677 |
Short Selling Information
The latest short interest is 1.54 million, so 6.99% of the outstanding shares have been sold short.
| Short Interest | 1.54M |
| Short Previous Month | 3.20M |
| Short % of Shares Out | 6.99% |
| Short % of Float | 7.99% |
| Short Ratio (days to cover) | 0.55 |
Income Statement
In the last 12 months, AIM ImmunoTech had revenue of $94,000 and -$13.28 million in losses. Loss per share was -$5.25.
| Revenue | 94,000 |
| Gross Profit | -28,000 |
| Operating Income | -10.27M |
| Pretax Income | -13.28M |
| Net Income | -13.28M |
| EBITDA | -10.11M |
| EBIT | -10.27M |
| Loss Per Share | -$5.25 |
Balance Sheet
The company has $5.88 million in cash and $4.57 million in debt, with a net cash position of $1.31 million or $0.06 per share.
| Cash & Cash Equivalents | 5.88M |
| Total Debt | 4.57M |
| Net Cash | 1.31M |
| Net Cash Per Share | $0.06 |
| Equity (Book Value) | 2.13M |
| Book Value Per Share | 0.26 |
| Working Capital | 69,000 |
Cash Flow
| Operating Cash Flow | -11.32M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 195,000 |
| Net Borrowing | 1.89M |
| Free Cash Flow | -11.32M |
| FCF Per Share | -$0.51 |
Margins
| Gross Margin | -29.79% |
| Operating Margin | -10,926.60% |
| Pretax Margin | -14,123.40% |
| Profit Margin | n/a |
| EBITDA Margin | -13,849.32% |
| EBIT Margin | -14,069.86% |
| FCF Margin | n/a |
Dividends & Yields
AIM ImmunoTech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -313.35% |
| Shareholder Yield | -313.35% |
| Earnings Yield | -227.72% |
| FCF Yield | -194.09% |
Analyst Forecast
The average price target for AIM ImmunoTech is $5.25, which is 1,888.64% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.25 |
| Price Target Difference | 1,888.64% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 9, 2026. It was a forward split with a ratio of 1.001:1.
| Last Split Date | Jan 9, 2026 |
| Split Type | Forward |
| Split Ratio | 1.001:1 |
Scores
AIM ImmunoTech has an Altman Z-Score of -75.8 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -75.8 |
| Piotroski F-Score | 2 |